Aspects of this disclosure generally are related to a medical device system including a high-density arrangement of transducers. In some embodiments, the transducers are configured to ablate or sense characteristics of tissue inside a bodily cavity.
Cardiac surgery was initially undertaken using highly invasive open procedures. A sternotomy, which is a type of incision in the center of the chest that separates the sternum was typically employed to allow access to the heart. In the past several decades, more and more cardiac operations are performed using intravascular or percutaneous techniques, where access to inner organs or other tissue is gained via a catheter.
Intravascular or percutaneous surgeries benefit patients by reducing surgery risk, complications and recovery time. However, the use of intravascular or percutaneous technologies also raises some particular challenges. Medical devices used in intravascular or percutaneous surgery need to be deployed via catheter systems which significantly increase the complexity of the device structure. As well, doctors do not have direct visual contact with the medical devices once the devices are positioned within the body.
One example of where intravascular or percutaneous medical techniques have been employed is in the treatment of a heart disorder called atrial fibrillation. Atrial fibrillation is a disorder in which spurious electrical signals cause an irregular heartbeat. Atrial fibrillation has been treated with open heart methods using a technique known as the “Cox-Maze procedure”. During this procedure, physicians create specific patterns of lesions in the left and right atria to block various paths taken by the spurious electrical signals. Such lesions were originally created using incisions, but are now typically created by ablating the tissue with various techniques including radio-frequency (RF) energy, microwave energy, laser energy and cryogenic techniques. The procedure is performed with a high success rate under the direct vision that is provided in open procedures, but is relatively complex to perform intravascularly or percutaneously because of the difficulty in creating the lesions in the correct locations. Various problems, potentially leading to severe adverse results, may occur if the lesions are placed incorrectly. It is particularly important to know the position of the various transducers which will be creating the lesions relative to cardiac features such as the pulmonary veins and mitral valve. The continuity, transmurality, and placement of the lesion patterns that are formed can impact the ability to block paths taken within the heart by spurious electrical signals. Other requirements for various ones of the transducers to perform additional functions such as, but not limited to, mapping various anatomical features, mapping electrophysiological activity, sensing tissue characteristics such as impedance and temperature and tissue stimulation can also complicate the operation of the employed medical device.
However, conventional transducer-based intra-bodily-cavity devices have relatively few transducers due to conventional technological limitations and, consequently, have difficulty gathering adequate information and performing proper lesion formation. Accordingly, a need in the art exists for improved intra-bodily-cavity transducer-based devices.
At least the above-discussed need is addressed and technical solutions are achieved by various embodiments of the present invention. In some embodiments, device systems exhibit enhanced capabilities for the deployment and the activation of various transducers, which may be located within a bodily cavity, such as an intra-cardiac cavity. In some embodiments, systems or a portion thereof may be percutaneously or intravascularly delivered to position the various transducers within the bodily cavity. Various ones of the transducers may be activated to distinguish tissue from blood and may be used to deliver positional information of the device relative to various anatomical features in the bodily cavity, such as the pulmonary veins and mitral valve in an atrium. Various ones of the transducers may employ characteristics such as blood flow detection, impedance change detection or deflection force detection to discriminate between blood and tissue. Various ones of the transducers may be used to treat tissue within a bodily cavity. Treatment may include tissue ablation by way of non-limiting example. Various ones of the transducers may be used to stimulate tissue within the bodily cavity. Stimulation can include pacing by way of non-limiting example. Other advantages will become apparent from the teaching herein to those of skill in the art.
In some embodiments, a medical device system may be summarized as including a structure that includes a plurality of elongate members, each of the elongate members including a proximal end, a distal end, and an intermediate portion between the proximal and distal ends. The medical device system further includes a plurality of electrodes located on the structure, the plurality of electrodes positionable in a bodily cavity. A first group of the electrodes is located on a first elongate member of the plurality of elongate members and a second group of the electrodes is located on a second elongate member of the plurality of elongate members. The structure is selectively moveable between a delivery configuration in which the structure is sized to be percutaneously delivered to the bodily cavity and a deployed configuration in which the structure is expanded to have a size too large to be percutaneously delivered to the bodily cavity. The intermediate portions of the elongate members are angularly arranged with respect to one another about a first axis when the structure is in the deployed configuration. Each electrode of the first group of the electrodes is intersected by a first plane having no thickness and each electrode of the second group of the electrodes is intersected by a second plane having no thickness when the structure is in the deployed configuration. The first and the second planes are non-parallel planes that intersect each other along a second axis, and at least a first electrode of the plurality of electrodes is intersected by each of the first plane and the second plane when the structure is in the deployed configuration. The first electrode is not intersected by each of the first axis and the second axis when the structure is in the deployed configuration.
In some embodiments, the second axis is parallel to the first axis. In some embodiments, the first axis and the second axis are collinear. In some embodiments, the first axis intersects at least one other electrode of the plurality of electrodes that does not include the first electrode when the structure is in the deployed configuration. In some embodiments, the second axis intersects at least one other electrode of the plurality of electrodes that does not include the first electrode when the structure is in the deployed configuration.
Each of the plurality of elongate members may include a curved portion having a curvature configured to cause the curved portion to extend along at least a portion of a respective curved path, the curvature configured to cause the curved path to intersect the first axis at each of a respective at least two spaced apart locations along the first axis when the structure is in the deployed configuration. At least some of the plurality of electrodes may be radially spaced about the first axis when the structure is in the deployed configuration. At least some of the plurality of electrodes may be circumferentially arranged about the first axis when the structure is in the deployed configuration. The intermediate portion of the first elongate member may overlap the intermediate portion of the second elongate member at a location on the structure passed through by the first axis when the structure is in the deployed configuration. The intermediate portion of the first elongate member may overlap the intermediate portion of the second elongate member at each of a first location on the structure passed through by the first axis and a second location on the structure passed through by the second axis when the structure is in the deployed configuration. Each of the plurality of elongate members may be arranged to be advanced distal end-first into the bodily cavity when the structure is in the delivery configuration. The intermediate portion of the first elongate member may be adjacent the intermediate portion of the second elongate member when the structure is in the deployed configuration.
In some embodiments, the first group of the electrodes may include a pair of adjacent ones of the electrodes located on the first elongate member. A region of space associated with a physical portion of the structure may be located between the respective electrodes of the pair of adjacent ones of the electrodes located on the first elongate member, the region of space intersected by the first plane when the structure is in the deployed configuration. The respective electrodes of the first group of the electrodes may be spaced along a length of a portion of the first elongate member, the length of the portion of the first elongate member extending along the first elongate member between the proximal and the distal ends of the first elongate member. The entirety of the length of the portion of the elongate member may be intersected by the first plane when the structure is in the deployed configuration. The first group of the electrodes, the second group of the electrodes, or each of both the first and the second groups of the electrodes may include three or more of the plurality of electrodes.
In some embodiments, the first plane may intersect every electrode that is located on the first elongate member when the structure is in the deployed configuration. In some embodiments, the second plane may intersect every electrode that is located on the second elongate member when the structure is in the deployed configuration. In some embodiments, the first group of the electrodes includes the first electrode and the second group of the electrodes does not include the first electrode. At least some of the plurality of electrodes may be arranged in a plurality of concentric ringed arrangements when the structure is in the deployed configuration, a first one of the plurality of concentric ringed arrangements having a fewer number of the electrodes than a second one of the plurality of concentric ringed arrangements. The first one of the plurality of concentric ringed arrangements may include the first electrode.
The first elongate member may include an edge interrupted by a notch, the notch located to expose at least a portion of at least a second electrode located on the second elongate member as viewed towards the second electrode along a direction parallel to a direction that the first axis extends along when the structure is in the deployed configuration. The second group of the electrodes may include the second electrode. The second electrode may be adjacent the first electrode when the structure is in the deployed configuration.
In some embodiments, the first elongate member may include a surface interrupted by a channel, the channel located to expose at least a portion of at least a second electrode located on the second elongate member as viewed towards the second electrode along a direction parallel to a direction that the first axis extends along when the structure is in the deployed configuration. In some embodiments, the first elongate member may include a jogged portion, the jogged portion undergoing at least one change in direction as the jogged portion extends between the proximal and the distal ends of the first elongate member. The jogged portion may be located to expose at least a portion of at least a second electrode located on the second elongate member as viewed towards the second electrode along a direction parallel to a direction that the first axis extends along when the structure is in the deployed configuration. In some embodiments, the intermediate portion of each elongate member of the plurality of elongate members includes a front surface and a back surface opposite across a thickness of the elongate member from the front surface. Each intermediate portion further includes a respective pair of side edges of the front surface, the back surface, or both the front surface and the back surface of the intermediate portion. The side edges of each pair of side edges are opposite to one another, each of the side edges of each pair of side edges extending between the proximal end and the distal end of the respective elongate member. The first elongate member may be positioned such that a first edge of the pair of side edges of the first elongate member crosses a second side edge of the pair of side edges of the second elongate member of the plurality of elongate members when the structure is in the deployed configuration. A portion of the first edge may form a recessed portion of the first elongate member that exposes at least a portion of a second electrode located on a portion of the front surface of the second elongate member as viewed normally to the portion of the front surface of the second elongate member when the structure is in the deployed configuration. The second group of the electrodes may include the second electrode.
In some embodiments, each of the respective intermediate portions of the elongate members each may include a thickness, a front surface, and a back surface opposite across the thickness from the front surface. The respective intermediate portions of the plurality of elongate members may be arranged front surface-toward-back surface in a stacked array when the structure is in the delivery configuration. The structure may further include a proximal portion and a distal portion, each of the proximal and the distal portions including a respective part of each of the plurality of elongate members, the proximal portion of the structure forming a first domed shape and the distal portion of the structure forming a second domed shape when the structure is in the deployed configuration.
The structure may include a proximal portion and a distal portion with the structure arranged to be advanced distal portion first into the bodily cavity when the structure is in the delivery configuration. In some embodiments, the proximal portion of the structure forms a first domed shape and the distal portion of the structure forms a second domed shape when the structure is in the deployed configuration, the proximal and the distal portions of the structure arranged in a clam shell configuration when the structure is in the deployed configuration.
In some embodiments, the intermediate portions of at least some of the plurality of elongate members are, when the structure is in the deployed configuration, sufficiently spaced from the first axis to position each of at least some of the plurality of the electrodes at respective locations suitable for contact with a tissue wall of the bodily cavity.
Various systems may include combinations and subsets of the systems summarized above.
In some embodiments, a medical device system may be summarized as including a plurality of transducers positionable in a bodily cavity and a structure on which the transducers are located. The structure includes a plurality of elongate members, each of the elongate members including a proximal end, a distal end, an intermediate portion positioned between the proximal end and the distal end, and a thickness. Each intermediate portion includes a front surface and a back surface opposite across the thickness of the elongate member from the front surface, and each intermediate portion further includes a respective pair of side edges of the front surface, the back surface, or both the front surface and the back surface. The side edges of each pair of side edges are opposite to one another, and the side edges of each pair of side edges extend between the proximal end and the distal end of the respective elongate member. The structure is selectively moveable between a delivery configuration in which the structure is sized for percutaneous delivery to a bodily cavity, and a deployed configuration in which the structure is sized too large for percutaneous delivery to the bodily cavity. At least a first elongate member of the plurality of elongate members is positioned such that a first edge of the pair of side edges of the first elongate member crosses a second side edge of the pair of side edges of a second elongate member of the plurality of elongate members when the structure is in the deployed configuration. A portion of the first edge forms a recessed portion of the first elongate member that exposes at least a portion of a transducer located on a portion of the front surface of the second elongate member as viewed normally to the portion of the front surface of the second elongate member when the structure is in the deployed configuration.
The recessed portion of the first elongate member may form at least a portion of a notch in the intermediate portion of the first elongate member, the notch extending towards a second edge of the pair of side edges of the first elongate member. The first elongate member may include a jogged portion, the jogged portion undergoing at least one change in direction as the jogged portion extends between the proximal and the distal ends of the first elongate member, the recessed portion of the first elongate member forming at least part of the jogged portion.
The intermediate portions of the elongate members may be angularly arranged with respect to one another about an axis when the structure is in the deployed configuration. At least some of the plurality of transducers may be radially spaced about an axis when the structure is in the deployed configuration. At least some of the plurality of transducers may be circumferentially arranged about an axis when the structure is in the deployed configuration. At least some of the plurality of transducers may be arranged in a plurality of concentric ringed arrangements when the structure is in the deployed configuration, a first one of the plurality of concentric ringed arrangements having a fewer number of the transducers than a second one of the plurality of concentric ringed arrangements. The first one of the plurality of concentric ringed arrangements may not include any of the plurality of transducers located on the second elongate member. The second one of the plurality of concentric ringed arrangements may include the transducer located on the portion of the front surface of the second elongate member. The first one of the plurality of concentric ringed arrangements may be adjacent the second one of the plurality of concentric ringed arrangements.
Each of the plurality of elongate members may be arranged to be advanced distal end-first into the bodily cavity when the structure is in the delivery configuration. The respective intermediate portions of the plurality of elongate members may be arranged front surface-toward-back surface in a stacked array when the structure is in the delivery configuration. The structure may further include a proximal portion and a distal portion, each of the proximal and the distal portions including a respective part of each of the plurality of elongate members, the proximal portion of the structure forming a first domed shape and the distal portion of the structure forming a second domed shape when the structure is in the deployed configuration.
The structure may include a proximal portion and a distal portion, with the structure arranged to be advanced distal portion first into the bodily cavity when the structure is in the delivery configuration. In some embodiments, the proximal portion of the structure forms a first domed shape and the distal portion of the structure forms a second domed shape when the structure is in the deployed configuration, the proximal and the distal portions of the structure arranged in a clam shell configuration when the structure is in the deployed configuration.
Various systems may include combinations and subsets of the systems summarized above.
In some embodiments, a medical device system may be summarized as including a plurality of electrodes positionable in a bodily cavity and a structure on which the electrodes are located. The structure includes a plurality of elongate members. The plurality of electrodes include a plurality of sets of the electrodes, each respective set of the electrodes located on a respective one of the elongate members. Each of the elongate members includes a proximal end, a distal end, an intermediate portion positioned between the proximal end and the distal end, and a thickness. Each intermediate portion includes a front surface and a back surface opposite across the thickness of the elongate member from the front surface. The structure is selectively moveable between a delivery configuration in which the structure is sized for percutaneous delivery to the bodily cavity and a deployed configuration in which the structure is sized too large for percutaneous delivery to the bodily cavity. A first elongate member of the plurality of elongate members is positioned such that a portion of the front surface of the first elongate member overlaps a portion of the respective front surface of each of at least a second elongate member of the plurality of elongate members as viewed normally to the portion of the front surface of the first elongate member when the structure is in the deployed configuration. At least a first electrode of the plurality of electrodes is located at least on the portion of the front surface of the first elongate member, and the portion of the front surface of the second elongate member faces the back surface of the first elongate member at least when the structure is in the deployed configuration.
Each of the front surfaces of the plurality of elongate members may face an outward direction of the structure when the structure is in the deployed configuration. The portion of the front surface of the second elongate member may face the back surface of the first elongate member when the structure is in the delivery configuration. The portion of the front surface of the second elongate member may contact the back surface of the first elongate member when the structure is in the deployed configuration. Each electrode in each set of the plurality of electrodes may be located solely on the front surface of a respective one of the elongate members.
The intermediate portions of the elongate members may be angularly arranged with respect to one another about an axis when the structure is in the deployed configuration. At least some of the plurality of electrodes may be radially spaced about the axis when the structure is in the deployed configuration. At least some of the plurality of electrodes may be circumferentially arranged about the axis when the structure is in the deployed configuration. The intermediate portion of the first elongate member may cross the intermediate portion of the second elongate member at a location on the structure intersected by the axis when the structure is in the deployed configuration. Each of the portion of the front surface of the first elongate member and the portion of the front surface of the second elongate member may be intersected by the axis when the structure is in the deployed configuration. The intermediate portion of the first elongate member may be adjacent the intermediate portion of the second elongate member when the structure is in the deployed configuration. At least one electrode of the plurality of electrodes may be intersected by the axis when the structure is in the deployed configuration. A particular electrode of the at least one electrode may be located adjacently to the first electrode on the portion of the front surface of the first elongate member. At least some of the plurality of electrodes may be arranged in a plurality of concentric ringed arrangements when the structure is in the deployed configuration, a first one of the plurality of concentric ringed arrangements having a fewer number of the electrodes than a second one of the plurality of concentric ringed arrangements. The first one of the plurality of concentric ringed arrangements may include the first electrode.
Each intermediate portion may further include a respective pair of side edges of the front surface, the back surface, or both the front surface and the back surface of the intermediate portion. The side edges of each pair of side edges are opposite to one another, and each of the side edges of each pair of side edges extend between the proximal end and the distal end of the respective elongate member. The first elongate member may be positioned such that a first edge of the pair of side edges of the first elongate member crosses a second side edge of the pair of side edges of the second elongate member when the structure is in the deployed configuration. A portion of the first edge may form a recessed portion of the first elongate member that exposes at least a portion of a second electrode located on the portion of the front surface of the second elongate member as viewed normally to the portion of the front surface of the second elongate member when the structure is in the deployed configuration.
Each of the plurality of elongate members may be arranged to be advanced distal end-first into the bodily cavity when the structure is in the delivery configuration. The respective intermediate portions of the plurality of elongate members may be arranged front surface-toward-back surface in a stacked array when the structure is in the delivery configuration. The structure may further include a proximal portion and a distal portion, each of the proximal and the distal portions including a respective part of each of the plurality of elongate members. In some embodiments, the proximal portion of the structure forms a first domed shape and the distal portion of the structure forms a second domed shape when the structure is in the deployed configuration.
The structure may include a proximal portion and a distal portion, with the structure arranged to be advanced distal portion first into the bodily cavity when the structure is in the delivery configuration. In some embodiments, the proximal portion of the structure forms a first domed shape and the distal portion of the structure forms a second domed shape when the structure is in the deployed configuration, the proximal and the distal portions of the structure arranged in a clam shell configuration when the structure is in the deployed configuration.
Various systems may include combinations and subsets of the systems summarized above.
In some embodiments, a medical device system may be summarized as including a plurality of electrodes positionable in a bodily cavity and a structure on which the electrodes are located. The structure includes a plurality of elongate members, each of the elongate members including a proximal end, a distal end, an intermediate portion positioned between the proximal end and the distal end, and a thickness. Each intermediate portion includes a front surface and a back surface opposite across the thickness of the elongate member from the front surface. Each intermediate portion further includes a respective pair of side edges of the front surface, the back surface, or both the front surface and the back surface. The side edges of each pair of side edges opposite to one another. The side edges of each pair of side edges extend between the proximal end and the distal end of the respective elongate member. The structure is selectively moveable between a delivery configuration in which the structure is sized for percutaneous delivery to a bodily cavity and a deployed configuration in which the structure is sized too large for percutaneous delivery to the bodily cavity. At least a first elongate member of the plurality of elongate members is positioned such that a first side edge of the pair of side edges of the first elongate member crosses a first side edge of the pair of side edges of a second elongate member of the plurality of elongate members at a first location and crosses a second side edge of the pair of side edges of the second elongate member at a second location when the structure is in the deployed configuration. Each of one or more of the plurality of electrodes is wholly located on a portion of the second elongate member, the portion of the second elongate member located between a first transverse line and a second transverse line when the structure is in the deployed configuration, the first transverse line extending across a first width of the second elongate member at the first location, and the second transverse line extending across a second width of the second elongate member at the second location.
The first width may be different than the second width. The first width and the second width may be widths of the front surface of the second elongate member. The one or more electrodes may include two or more of the plurality of electrodes. At least a portion of an electrode of the plurality of electrodes may be located on the portion of the second elongate member.
A first electrode of the one or more of the plurality of electrodes may include a first electrode edge that forms part of a periphery of an electrically conductive surface of the first electrode, the first electrode edge arranged to follow a portion of the first side edge of the first elongate member between the first location and the second location when the structure is in the deployed configuration. The first electrode may include a second electrode edge opposite across the electrically conductive surface from the first electrode edge, the second electrode edge forming part of the periphery of the electrically conductive surface of the first electrode. The second electrode edge may be arranged to follow a portion of one of the pair of side edges of the second elongate member.
The intermediate portions of the elongate members may be angularly arranged with respect to one another about an axis when the structure is in the deployed configuration. At least some of the plurality of electrodes may be radially spaced about the axis when the structure is in the deployed configuration. At least some of the plurality of electrodes may be circumferentially arranged about the axis when the structure is in the deployed configuration. The intermediate portion of the first elongate member may cross the intermediate portion of the second elongate member at a location on the structure intersected by the axis when the structure is in the deployed configuration. The intermediate portion of the first elongate member may be adjacent the intermediate portion of the second elongate member when the structure is in the deployed configuration. A particular one of the plurality of electrodes may be intersected by the axis when the structure is in the deployed configuration. The one or more electrodes may include a first electrode, the first electrode located on the structure adjacent the particular one of the plurality of electrodes when the structure is in the deployed configuration. The one or more electrodes may include a first electrode, and at least some of the plurality of electrodes may be arranged in a plurality of concentric ringed arrangements when the structure is in the deployed configuration. In some embodiments, a first one of the plurality of concentric ringed arrangements has a fewer number of the electrodes than a second one of the plurality of concentric ringed arrangements. The first one of the plurality of concentric ringed arrangements may include the first electrode.
A portion of the first side edge of the first elongate member extending between the first location and the second location may form a recessed portion of the first elongate member that exposes at least a portion of a particular electrode of the one or more electrodes as viewed normally to a surface of the exposed portion of the particular electrode of the one or more electrodes when the structure is in the deployed configuration.
Each of the plurality of elongate members may be arranged to be advanced distal end-first into the bodily cavity when the structure is in the delivery configuration. The respective intermediate portions of the plurality of elongate members may be arranged front surface-toward-back surface in a stacked array when the structure is in the delivery configuration. The structure may further include a proximal portion and a distal portion, each of the proximal and the distal portions including a respective part of each of the plurality of elongate members. In some embodiments, the proximal portion of the structure forms a first domed shape and the distal portion of the structure forms a second domed shape when the structure is in the deployed configuration.
The structure may include a proximal portion and a distal portion, with the structure arranged to be advanced distal portion first into the bodily cavity when the structure is in the delivery configuration. In some embodiments, the proximal portion of the structure forms a first domed shape and the distal portion of the structure forms a second domed shape when the structure is in the deployed configuration, the proximal and the distal portions of the structure arranged in a clam shell configuration when the structure is in the deployed configuration.
Various systems may include combinations and subsets of all the systems summarized above.
It is to be understood that the attached drawings are for purposes of illustrating aspects of various embodiments and may include elements that are not to scale.
In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments of the invention. However, one skilled in the art will understand that the invention may be practiced without one or more of these details. In other instances, well-known structures (e.g., structures associated with radio-frequency (RF) ablation and electronic controls such as multiplexers) have not been shown or described in detail to avoid unnecessarily obscuring descriptions of various embodiments of the invention.
Reference throughout this specification to “one embodiment” or “an embodiment” or “an example embodiment” or “an illustrated embodiment” or “a particular embodiment” and the like means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” or “in an example embodiment” or “in this illustrated embodiment” or “in this particular embodiment” and the like in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures or characteristics of different embodiments may be combined in any suitable manner to form one or more other embodiments.
It is noted that, unless otherwise explicitly noted or required by context, the word “or” is used in this disclosure in a non-exclusive sense. In addition, unless otherwise explicitly noted or required by context, the word “set” is intended to mean one or more.
Further, the phrase “at least” is used herein at times to emphasize the possibility that other elements can exist besides those explicitly listed. However, unless otherwise explicitly noted (such as by the use of the term “only”) or required by context, non-usage herein of the phrase “at least” does not exclude the possibility that other elements can exist besides those explicitly listed. For example, the phrase, “activation of at least transducer A” includes activation of transducer A by itself, as well as activation of transducer A and activation of one or more other additional elements besides transducer A. In the same manner, the phrase, “activation of transducer A” includes activation of transducer A by itself, as well as activation of transducer A and activation of one or more other additional elements besides transducer A. However, the phrase, “activation of only transducer A” includes only activation of transducer A, and excludes activation of any other elements besides transducer A.
The word “ablation” as used in this disclosure should be understood to include any disruption to certain properties of tissue. Most commonly, the disruption is to the electrical conductivity and is achieved by heating, which can be generated with resistive or radio-frequency (RF) techniques for example. Other properties, such as mechanical or chemical, and other means of disruption, such as optical, are included when the term “ablation” is used.
The word “fluid” as used in this disclosure should be understood to include any fluid that can be contained within a bodily cavity or can flow into or out of, or both into and out of a bodily cavity via one or more bodily openings positioned in fluid communication with the bodily cavity. In the case of cardiac applications, fluid such as blood will flow into and out of various intra-cardiac cavities (e.g., a left atrium or right atrium).
The words “bodily opening” as used in this disclosure should be understood to include a naturally occurring bodily opening or channel or lumen; a bodily opening or channel or lumen formed by an instrument or tool using techniques that can include, but are not limited to, mechanical, thermal, electrical, chemical, and exposure or illumination techniques; a bodily opening or channel or lumen formed by trauma to a body; or various combinations of one or more of the above. Various elements having respective openings, lumens or channels and positioned within the bodily opening (e.g., a catheter sheath or catheter introducer) may be present in various embodiments. These elements may provide a passageway through a bodily opening for various devices employed in various embodiments.
The words “bodily cavity” as used in this disclosure should be understood to mean a cavity in a body. The bodily cavity may be a cavity provided in a bodily organ (e.g., an intra-cardiac cavity of a heart).
The word “tissue” as used in some embodiments in this disclosure should be understood to include any surface-forming tissue that is used to form a surface of a body or a surface within a bodily cavity, a surface of an anatomical feature or a surface of a feature associated with a bodily opening positioned in fluid communication with the bodily cavity. The tissue can include part or all of a tissue wall or membrane that defines a surface of the bodily cavity. In this regard, the tissue can form an interior surface of the cavity that surrounds a fluid within the cavity. In the case of cardiac applications, tissue can include tissue used to form an interior surface of an intra-cardiac cavity such as a left atrium or right atrium. In some embodiments, the word tissue can refer to a tissue having fluidic properties (e.g., blood).
The term “transducer” as used in this disclosure should be interpreted broadly as any device capable of distinguishing between fluid and tissue, sensing temperature, creating heat, ablating tissue, measuring electrical activity of a tissue surface, stimulating tissue, or any combination thereof. A transducer can convert input energy of one form into output energy of another form. Without limitation, a transducer can include an electrode that functions as, or as part of, a sensing device included in the transducer, an energy delivery device included in the transducer, or both a sensing device and an energy delivery device included in the transducer. A transducer may be constructed from several parts, which may be discrete components or may be integrally formed.
The term “activation” as used in this disclosure should be interpreted broadly as making active a particular function as related to various transducers disclosed in this disclosure. Particular functions can include, but are not limited to, tissue ablation, sensing electrophysiological activity, sensing temperature and sensing electrical characteristics (e.g., tissue impedance). For example, in some embodiments, activation of a tissue ablation function of a particular transducer is initiated by causing energy sufficient for tissue ablation from an energy source device system to be delivered to the particular transducer. Alternatively, in this example, the activation can be deemed to be initiated when the particular transducer causes a temperature sufficient for the tissue ablation due to the energy provided by the energy source device system. Also in this example, the activation can last for a duration of time concluding when the ablation function is no longer active, such as when energy sufficient for the tissue ablation is no longer provided to the particular transducer. Alternatively, in this example, the activation period can be deemed to be concluded when the temperature caused by the particular transducer is below the temperature sufficient for the tissue ablation. In some contexts, however, the word “activation” can merely refer to the initiation of the activating of a particular function, as opposed to referring to both the initiation of the activating of the particular function and the subsequent duration in which the particular function is active. In these contexts, the phrase or a phrase similar to “activation initiation” may be used.
The term “program” in this disclosure should be interpreted as a set of instructions or modules that can be executed by one or more components in a system, such as a controller system or data processing device system, in order to cause the system to perform one or more operations. The set of instructions or modules can be stored by any kind of memory device, such as those described subsequently with respect to the memory device system 130 shown in
The word “device” and the phrase “device system” both are intended to include one or more physical devices or subdevices (e.g., pieces of equipment) that interact to perform one or more functions, regardless of whether such devices or subdevices are located within a same housing or different housings. In this regard, for example, the phrase “catheter device” could equivalently be referred to as a “catheter device system”.
In some contexts, the term “adjacent” is used in this disclosure to refer to objects that do not have another substantially similar object between them. For example, object A and object B could be considered adjacent if they contact each other (and, thus, it could be considered that no other object is between them), or if they do not contact each other, but no other object that is substantially similar to object A, object B, or both objects A and B, depending on context, is between them.
Further, the phrase “in response to” might be used in the following context, where an event A occurs in response to the occurrence of an event B. In this regard, such phrase can include, for example, that at least the occurrence of the event B causes or triggers the event A.
The data processing device system 110 includes one or more data processing devices that implement methods by controlling or interacting with various structural components described herein, including, but not limited to, various structural components illustrated in the other
The memory device system 130 includes one or more processor-accessible memory devices configured to store information, including the information needed to execute the methods implemented by the data processing device system 110. The memory device system 130 may be a distributed processor-accessible memory device system including multiple processor-accessible memory devices communicatively connected to the data processing device system 110 via a plurality of computers and/or devices. On the other hand, the memory device system 130 need not be a distributed processor-accessible memory system and, consequently, may include one or more processor-accessible memory devices located within a single housing or data processing device.
Each of the phrases “processor-accessible memory” and “processor-accessible memory device” is intended to include any processor-accessible data storage device, whether volatile or nonvolatile, electronic, magnetic, optical, or otherwise, including but not limited to, registers, floppy disks, hard disks, Compact Discs, DVDs, flash memories, ROMs, and RAMs. In some embodiments, each of the phrases “processor-accessible memory” and “processor-accessible memory device” is intended to include a non-transitory computer-readable storage medium. And in some embodiments, the memory device system 130 can be considered a non-transitory computer-readable storage medium system.
The phrase “communicatively connected” is intended to include any type of connection, whether wired or wireless, between devices, data processors, or programs in which data may be communicated. Further, the phrase “communicatively connected” is intended to include a connection between devices or programs within a single data processor, a connection between devices or programs located in different data processors, and a connection between devices not located in data processors at all. In this regard, although the memory device system 130 is shown separately from the data processing device system 110 and the input-output device system 120, one skilled in the art will appreciate that the memory device system 130 may be located completely or partially within the data processing device system 110 or the input-output device system 120. Further in this regard, although the input-output device system 120 is shown separately from the data processing device system 110 and the memory device system 130, one skilled in the art will appreciate that such system may be located completely or partially within the data processing system 110 or the memory device system 130, depending upon the contents of the input-output device system 120. Further still, the data processing device system 110, the input-output device system 120, and the memory device system 130 may be located entirely within the same device or housing or may be separately located, but communicatively connected, among different devices or housings. In the case where the data processing device system 110, the input-output device system 120, and the memory device system 130 are located within the same device, the system 100 of
The input-output device system 120 may include a mouse, a keyboard, a touch screen, another computer, or any device or combination of devices from which a desired selection, desired information, instructions, or any other data is input to the data processing device system 110. The input-output device system may include a user-activatable control system that is responsive to a user action. The input-output device system 120 may include any suitable interface for receiving information, instructions or any data from other devices and systems described in various ones of the embodiments. In this regard, the input-output device system 120 may include various ones of other systems described in various embodiments. For example, the input-output device system 120 may include at least a portion of a transducer-based device system. The phrase “transducer-based device system” is intended to include one or more physical systems that include one or more physical devices that include transducers.
The input-output device system 120 also may include an image generating device system, a display device system, a processor-accessible memory device, or any device or combination of devices to which information, instructions, or any other data is output by the data processing device system 110. In this regard, if the input-output device system 120 includes a processor-accessible memory device, such memory device may or may not form part or all of the memory device system 130. The input-output device system 120 may include any suitable interface for outputting information, instructions or data to other devices and systems described in various ones of the embodiments. In this regard, the input-output device system may include various other devices or systems described in various embodiments. For example, the input-output device system may include a portion of a transducer-based device system.
Various embodiments of transducer-based devices are described herein. Some of the described devices are medical devices that are percutaneously or intravascularly deployed. Some of the described devices are moveable between a delivery or unexpanded configuration in which a portion of the device is sized for passage through a bodily opening leading to a bodily cavity, and an expanded or deployed configuration in which the portion of the device has a size too large for passage through the bodily opening leading to the bodily cavity. An example of an expanded or deployed configuration is when the portion of the transducer-based device is in its intended-deployed-operational state inside the bodily cavity. Another example of the expanded or deployed configuration is when the portion of the transducer-based device is being changed from the delivery configuration to the intended-deployed-operational state to a point where the portion of the device now has a size too large for passage through the bodily opening leading to the bodily cavity.
In some example embodiments, the device includes transducers that sense characteristics (e.g., convective cooling, permittivity, force) that distinguish between fluid, such as a fluidic tissue (e.g., blood), and tissue forming an interior surface of the bodily cavity. Such sensed characteristics can allow a medical device system to map the cavity, for example using positions of openings or ports into and out of the cavity to determine a position or orientation (i.e., pose), or both of the portion of the device in the bodily cavity. In some example embodiments, the described devices are capable of ablating tissue in a desired pattern within the bodily cavity. In some example embodiments, the devices are capable of sensing characteristics (e.g., electrophysiological activity) indicative of whether an ablation has been successful. In some example embodiments, the devices are capable of providing stimulation (e.g., electrical stimulation) to tissue within the bodily cavity. Electrical stimulation may include pacing.
Transducer-based device 200 can be percutaneously or intravascularly inserted into a portion of the heart 202, such as an intra-cardiac cavity like left atrium 204. In this example, the transducer-based device 200 is part of a catheter 206 inserted via the inferior vena cava 208 and penetrating through a bodily opening in transatrial septum 210 from right atrium 212. In other embodiments, other paths may be taken.
Catheter 206 includes an elongated flexible rod or shaft member appropriately sized to be delivered percutaneously or intravascularly. Various portions of catheter 206 may be steerable. Catheter 206 may include one or more lumens (not shown). The lumen(s) may carry one or more communications or power paths, or both. For example, the lumens(s) may carry one or more electrical conductors 216 (two shown in this embodiment). Electrical conductors 216 provide electrical connections to device 200 that are accessible externally from a patient in which the transducer-based device 200 is inserted.
Transducer-based device 200 includes a frame or structure 218 which assumes an unexpanded configuration for delivery to left atrium 204. Structure 218 is expanded (i.e., shown in a deployed or expanded configuration in
The elongate members 304 are arranged in a frame or structure 308 that is selectively movable between an unexpanded or delivery configuration (i.e., as shown in
The flexible circuit structure 401 can be formed by various techniques including flexible printed circuit techniques. In some embodiments, the flexible circuit structure 401 includes various layers including flexible layers 403a, 403b and 403c (i.e., collectively flexible layers 403). In some embodiments, each of flexible layers 403 includes an electrical insulator material (e.g., polyimide). One or more of the flexible layers 403 can include a different material than another of the flexible layers 403. In some embodiments, the flexible circuit structure 401 includes various electrically conductive layers 404a, 404b and 404c (collectively electrically conductive layers 404) that are interleaved with the flexible layers 403. In some embodiments, each of the electrically conductive layers 404 is patterned to form various electrically conductive elements. For example, electrically conductive layer 404a is patterned to form a respective electrode 415 of each of the transducers 406. Electrodes 415 have respective electrode edges 415-1 that form a periphery of an electrically conductive surface associated with the respective electrode 415.
Returning to
In some embodiments, electrodes 415 are employed to selectively deliver RF energy to various tissue structures within a bodily cavity (not shown) (e.g., an intra-cardiac cavity). The energy delivered to the tissue structures may be sufficient for ablating portions of the tissue structures. The energy delivered to the tissue may be delivered to cause monopolar tissue ablation, bipolar tissue ablation or blended monopolar-bipolar tissue ablation by way of non-limiting example. In some embodiments, each electrode 415 is employed to sense an electrical potential in the tissue proximate the electrode 415. In some embodiments, each electrode 415 is employed in the generation of an intra-cardiac electrogram. In some embodiments, each resistive member 409 is positioned adjacent a respective one of the electrodes 415. In some embodiments, each of the resistive members 409 is positioned in a stacked or layered array with a respective one of the electrodes 415 to form a respective one of the transducers 406. In some embodiments, the resistive members 409 are connected in series to allow electrical current to pass through all of the resistive members 409. In some embodiments, leads 410a are arranged to allow for a sampling of electrical voltage in between each resistive members 409. This arrangement allows for the electrical resistance of each resistive member 409 to be accurately measured. The ability to accurately measure the electrical resistance of each resistive member 409 may be motivated by various reasons including determining temperature values at locations at least proximate the resistive member 409 based at least on changes in the resistance caused by convective cooling effects (e.g., as provided by blood flow). In some embodiments in which the transducer-based device is deployed in a bodily cavity (e.g., when the transducer-based device takes the form of a catheter device arranged to be percutaneously or intravascularly delivered to a bodily cavity), it may be desirable to perform various mapping procedures in the bodily cavity. For example, when the bodily cavity is an intra-cardiac cavity, a desired mapping procedure can include mapping electrophysiological activity in the intra-cardiac cavity. Other desired mapping procedures can include mapping of various anatomical features within a bodily cavity. An example of the mapping performed by devices according to various embodiments may include locating the position of the ports of various bodily openings positioned in fluid communication with a bodily cavity. For example, in some embodiments, it may be desired to determine the locations of various ones of the pulmonary veins or the mitral valve that each interrupts an interior surface of an intra-cardiac cavity such as a left atrium.
In some example embodiments, the mapping is based at least on locating bodily openings by differentiating between fluid and tissue (e.g., tissue defining a surface of a bodily cavity). There are many ways to differentiate tissue from a fluid such as blood or to differentiate tissue from a bodily opening in case a fluid is not present. Four approaches may include by way of non-limiting example:
1. The use of convective cooling of heated transducer elements by fluid. An arrangement of slightly heated transducers that is positioned adjacent to the tissue that forms the interior surface(s) of a bodily cavity and across the ports of the bodily cavity will be cooler at the areas which are spanning the ports carrying the flow of fluid.
2. The use of tissue impedance measurements. A set of transducers positioned adjacently to tissue that forms the interior surface(s) of a bodily cavity and across the ports of the bodily cavity can be responsive to electrical tissue impedance. Typically, heart tissue will have higher associated tissue impedance values than the impedance values associated with blood.
3. The use of the differing change in dielectric constant as a function of frequency between blood and tissue. A set of transducers positioned around the tissue that forms the interior surface(s) of the atrium and across the ports of the atrium monitors the ratio of the dielectric constant from 1 KHz to 100 KHz. Such can be used to determine which of those transducers are not proximate to tissue, which is indicative of the locations of the ports.
4. The use of transducers that sense force (i.e., force sensors). A set of force detection transducers positioned around the tissue that forms the interior surface(s) of a bodily cavity and across the bodily openings or ports of the bodily cavity can be used to determine which of the transducers are not engaged with the tissue, which may be indicative of the locations of the ports.
Referring to
Transducer-activation device system 322 includes an input-output device system 320 (e.g., an example of 120 from
Transducer-activation device system 322 may also include an energy source device system 340 including one or more energy source devices connected to transducers 306. In this regard, although
In any event, the number of energy source devices in the energy source device system 340 is fewer than the number of transducers in some embodiments. The energy source device system 340 may, for example, be connected to various selected transducers 306 to selectively provide energy in the form of electrical current or power (e.g., RF energy), light or low temperature fluid to the various selected transducers 306 to cause ablation of tissue. The energy source device system 340 may, for example, selectively provide energy in the form of electrical current to various selected transducers 306 and measure a temperature characteristic, an electrical characteristic, or both at a respective location at least proximate each of the various transducers 306. The energy source device system 340 may include as its energy source devices various electrical current sources or electrical power sources. In some embodiments, an indifferent electrode 326 is provided to receive at least a portion of the energy transmitted by at least some of the transducers 306. Consequently, although not shown in
It is understood that input-output device system 320 may include other systems. In some embodiments, input-output device system 320 may optionally include energy source device system 340, transducer-based device 300 or both energy source device system 340 and transducer-based device 300 by way of non-limiting example.
Structure 308 can be delivered and retrieved via a catheter member, for example a catheter sheath 312. In some embodiments, a structure provides expansion and contraction capabilities for a portion of a medical device (e.g., an arrangement, distribution or array of transducers 306). The transducers 306 can form part of, be positioned or located on, mounted or otherwise carried on the structure and the structure may be configurable to be appropriately sized to slide within catheter sheath 312 in order to be deployed percutaneously or intravascularly.
In a manner similar to that described in co-assigned International Application No.: PCT/US2012/022061 and co-assigned International Application No.: PCT/US2012/022062, each of the elongate members 304 is arranged in a fanned arrangement 370 in
The transducers 306 can be arranged in various distributions or arrangements in various embodiments. In some embodiments, various ones of the transducers 306 are spaced apart from one another in a spaced apart distribution in the delivery configuration shown in
In various example embodiments, at least some of the plurality of transducers 306 include respective electrodes 315 (seven called out in each of
Various conventional percutaneous or intravascular transducer-based device systems employ, or have employed, relatively low numbers of transducers typically on the order of 64 or fewer transducers or a number of transducers arranged with a relatively low spatial distribution density (e.g., a relatively low number of transducers arranged per a given area). Various embodiments disclosed in this detailed description may employ distributions of transducers having relatively high spatial densities (e.g., a relatively high number of transducers arranged per a given region of space) than conventionally employed. Increased number of transducers or increased spatial densities of transducers within a particular distribution of the transducers may be motivated for various reasons. For example, increased numbers of transducers may allow for higher spatial densities in the distributions of the transducers to allow the transducers to interact with a tissue region of a bodily cavity with greater resolution and accuracy. The interactions may include ablation, temperature detection, impedance detection, electrophysiological activity detection and tissue stimulation by way of non-limiting example. In some case, distributions of transducers having relatively high spatial densities may provide enhanced diagnostic or treatment procedures performed on a given tissue region by allowing for the interaction of a greater number of transducers with the given tissue region. Various embodiments disclosed in this detailed description may employ 100 or more transducers, 200 or more transducers or even 300 or more transducers. Various transducer-based devices disclosed in this detailed description (e.g., as depicted at least in part in
In some embodiments, the intermediate portion 309 of first elongate member 304a overlaps the intermediate portion 309 of a second elongate member 304b at a location on structure 308 passed through by first axis 335a when structure 308 is in the deployed configuration. In some embodiments, the intermediate portions 309 of the first elongate member 304a and the second elongate member 304b cross at a location on structure 308 passed through, or intersected, by first axis 335a when structure 308 is in the deployed configuration. In some embodiments, the intermediate portion 309 of first elongate member 304a is adjacent the intermediate portion 309 of the second elongate member 304b when structure 308 is in the deployed configuration. In various embodiments, the intermediate portions 309 of at least some of the plurality of elongate members 304 are, when the structure 309 is in the deployed configuration, sufficiently spaced from the first axis 335a to position each of at least some of the plurality of the electrodes 315 at respective locations suitable for contact with a tissue wall of the bodily cavity (not shown in
In various embodiments, at least some of the transducers 306 are radially spaced about first axis 335a when structure 308 is in the deployed configuration. For example, various ones of the electrodes 315 are radially spaced about first axis 335a in the deployed configuration in at least some of the embodiments associated with various ones of
Each of the first plane 342a and the second plane 344a are non-parallel planes that intersect each other along a second axis 337a. In some embodiments, second axis 337a is parallel to first axis 335a. In some embodiments, first axis 335a and second axis 337a are collinear. In some embodiments, the first axis 335a and the second axis 337a form a single axis. In other embodiments, different spatial relationships may exist between first axis 335a and second axis 337a. In some embodiments, the electrodes 315 are arranged in a spatial distribution in which a first electrode 315q associated with transducer 306q is intersected by each of the first plane 342a and the second plane 344a when the structure 308 is in the deployed configuration. In some embodiments, first electrode 315q is not intersected by first axis 335a when structure 308 is in the deployed configuration. In some embodiments, first electrode 315q is not intersected by second axis 337a when structure 308 is in the deployed configuration. In some embodiments, the first group 336a of electrodes 315 includes first electrode 315q. In some embodiments, the second group of electrodes 338a does not include first electrode 315q. In various embodiments, the first axis 335a, the second axis 337a or each of the first axis 335a and the second axis 337a intersects at least one electrode 315 located on structure 308 (e.g., electrode 315r associated with transducer 306r in
In various embodiments, each of the first group 336a and the second group 338a includes two or more of the electrodes 315. In some embodiments, the first group 336a, the second group 338a or each of both the first group 336a and the second group 338a includes three or more of the electrodes 315. In various embodiments, the first group 336a, the second group 338a or each of both the first group 336a and the second group 338a includes a pair of adjacent electrodes 315 located on a respective one of the first elongate member 304a and the second elongate member 304b. In some of these various embodiments, a region of space associated with a physical portion of structure 308 (e.g., an elongate member 304 portion) is located between the respective electrodes 315 of the pair of adjacent electrodes 315 included in the first group 336a, and the region of space is intersected by the first plane 342a when the structure 308 is in the deployed configuration. In some embodiments, the respective electrodes 315 of the first group 336a are spaced along a length of a portion of the first elongate member 304a, the length extending between the respective distal and proximal ends 305, 307 (not called out in
In some embodiments, the second axis 337a is not collinear with the first axis 335a. In some embodiments, the second axis 337a and the first axis 335a do not form a single axis. In some embodiments, the second axis 337a does not intersect the first axis 335a.
In various embodiments, particular spatial distributions of electrodes or transducers similar to the ones employed in
Other spatial characteristics are associated with the distribution of transducers 306/electrodes 315 associated with various embodiments associated with
In some example embodiments, one or more of the electrodes 315 are wholly located on the portion 348a of the second elongate member 304b when the structure 308 is in the deployed configuration. For example, electrode 315u is wholly located on the portion 348a (which is rectangular in some embodiments such as
It may be noted that distances between adjacent ones of the elongate members 304 shown in
In various embodiments, the respective shape of various electrically conductive surfaces (e.g., energy transmission surfaces 319) of various ones of the electrodes 315 vary among the electrodes 315. In various embodiments, the respective shape of various electrically conductive surfaces (e.g., energy transmission surfaces 319) of various ones of the electrodes 315 vary among the electrodes 315 in accordance with their proximity to first axis 335a. In various embodiments, one or more dimensions or sizes of various electrically conductive surfaces (e.g., energy transmission surfaces 319) of various ones of the electrodes 315 vary among the electrodes 315. In various embodiments, one or more dimensional sizes of various electrically conductive surfaces (e.g., energy transmission surfaces 319) of various ones of the electrodes 315 vary in accordance with their proximity to first axis 335a. The shape or size variances associated with various ones of the electrodes 315 may be motivated for various reasons. For example, in various embodiments, the shapes or sizes of various ones of the electrodes 315 may be controlled in response to various ones of the aforementioned size or dimensional constraints.
Referring to
It may be noted that although the distributions of transducers 306/electrodes 315 associated with structure 313 have differences from the distribution of transducers 306/electrodes 315 associated with structure 308, there are also similarities. The respective intermediate portions 309 of various ones of the elongate members 304 (five called out in each of
Each of the first plane 342b and the second plane 344c are non-parallel planes that intersect each other along a second axis 337c (represented by a symbol “●” in
In some embodiments, the second axis 337c is not collinear with the first axis 335b. In some embodiments, the second axis 337c and the first axis 335b do not form a single axis. In some embodiments, the second axis 337c does not intersect the first axis 335b.
Embodiments associated with
In some embodiments associated with
In at least one particular embodiment, various portions of the front surface 318a of the first elongate member 304d overlap various portions of the front surface 318a of each of several ones of the plurality of elongate members 304 when structure 313 is in the deployed configuration. In at least one particular embodiment, various portions of the front surface 318a of the first elongate member 304d overlap various portions of the front surface 318a of every other one of the plurality of elongate members 304 when structure 313 is in the deployed configuration. In at least one particular embodiment associated with
In
In various embodiments, first elongate member 304d includes a second recessed portion 328b (called out in
In various embodiments associated with
In a manner similar to embodiments associated with
In at least one particular embodiment associated with
In other embodiments, various ones of the recessed portions 328 may take a form other than a notch (e.g., notch 330a). For example,
While some of the embodiments disclosed above are described with examples of cardiac mapping, the same or similar embodiments may be used for mapping other bodily organs, for example gastric mapping, bladder mapping, arterial mapping and mapping of any lumen or cavity into which the devices of the present invention may be introduced.
While some of the embodiments disclosed above are described with examples of cardiac ablation, the same or similar embodiments may be used for ablating other bodily organs or any lumen or cavity into which the devices of the present invention may be introduced.
Subsets or combinations of various embodiments described above can provide further embodiments.
These and other changes can be made to the invention in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the invention to the specific embodiments disclosed in the specification and the claims, but should be construed to include other transducer-based device systems including all medical treatment device systems and medical diagnostic device systems in accordance with the claims. Accordingly, the invention is not limited by the disclosure, but instead its scope is to be determined entirely by the following claims.
This application: (a) is a continuation-in-part of prior International Application No. PCT/US2012/022061, which has an international filing date of Jan. 20, 2012, and which claims the benefit of each of U.S. Provisional Application No. 61/435,213, filed Jan. 21, 2011; U.S. Provisional Application No. 61/485,987, filed May 13, 2011; U.S. Provisional Application No. 61/488,639, filed May 20, 2011; and U.S. Provisional Application No. 61/515,141, filed Aug. 4, 2011; (b) is a continuation-in-part of prior International Application No. PCT/US2012/022062, which has an international filing date of Jan. 20, 2012, and which claims the benefit of each of U.S. Provisional Application No. 61/435,213, filed Jan. 21, 2011; U.S. Provisional Application No. 61/485,987, filed May 13, 2011; U.S. Provisional Application No. 61/488,639, filed May 20, 2011; and U.S. Provisional Application No. 61/515,141, filed Aug. 4, 2011; and (c) claims the benefit of each of U.S. Provisional Application No. 61/649,734, filed May 21, 2012; U.S. Provisional Application No. 61/670,881, filed Jul. 12, 2012; U.S. Provisional Application No. 61/723,311, filed Nov. 6, 2012; and U.S. Provisional Application No. 61/734,750, filed Dec. 7, 2012. The entire disclosure of each of the applications cited in this Cross-Reference to Related Applications Section is hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4114202 | Roy et al. | Sep 1978 | A |
4164046 | Cooley | Aug 1979 | A |
4225148 | Andersson | Sep 1980 | A |
4240441 | Khalil | Dec 1980 | A |
4263680 | Reul et al. | Apr 1981 | A |
4273128 | Lary | Jun 1981 | A |
4411266 | Cosman | Oct 1983 | A |
4490859 | Black et al. | Jan 1985 | A |
4543090 | McCoy | Sep 1985 | A |
4699147 | Chilson et al. | Oct 1987 | A |
4770187 | Lash et al. | Sep 1988 | A |
4787369 | Allred, III et al. | Nov 1988 | A |
4794912 | Lia | Jan 1989 | A |
4850957 | Summers | Jul 1989 | A |
4887613 | Farr et al. | Dec 1989 | A |
4890602 | Hake | Jan 1990 | A |
4890612 | Kensey | Jan 1990 | A |
4893613 | Hake | Jan 1990 | A |
4895166 | Farr et al. | Jan 1990 | A |
4905667 | Foerster et al. | Mar 1990 | A |
4921499 | Hoffman et al. | May 1990 | A |
4940064 | Desai | Jul 1990 | A |
4942788 | Farr et al. | Jul 1990 | A |
4979514 | Sekii et al. | Dec 1990 | A |
4998933 | Eggers et al. | Mar 1991 | A |
5026384 | Farr et al. | Jun 1991 | A |
5047047 | Yoon | Sep 1991 | A |
5122137 | Lennox | Jun 1992 | A |
5127902 | Fischell | Jul 1992 | A |
5156151 | Imran | Oct 1992 | A |
5174299 | Nelson | Dec 1992 | A |
5176693 | Pannek, Jr. | Jan 1993 | A |
5178620 | Eggers et al. | Jan 1993 | A |
5192291 | Pannek, Jr. | Mar 1993 | A |
5195505 | Josefsen | Mar 1993 | A |
5201316 | Pomeranz et al. | Apr 1993 | A |
5228442 | Imran | Jul 1993 | A |
5242386 | Holzer | Sep 1993 | A |
5245987 | Redmond et al. | Sep 1993 | A |
5255679 | Imran | Oct 1993 | A |
5279299 | Imran | Jan 1994 | A |
5293869 | Edwards et al. | Mar 1994 | A |
5312435 | Nash et al. | May 1994 | A |
5317952 | Immega | Jun 1994 | A |
5324284 | Imran | Jun 1994 | A |
5327889 | Imran | Jul 1994 | A |
5341807 | Nardella | Aug 1994 | A |
5345936 | Pomeranz et al. | Sep 1994 | A |
5351679 | Mayzels et al. | Oct 1994 | A |
5366443 | Eggers et al. | Nov 1994 | A |
5370679 | Atlee, III | Dec 1994 | A |
5379773 | Hornsby | Jan 1995 | A |
5397321 | Houser et al. | Mar 1995 | A |
5419767 | Eggers et al. | May 1995 | A |
5450860 | O'Connor | Sep 1995 | A |
5465717 | Imran et al. | Nov 1995 | A |
5478353 | Yoon | Dec 1995 | A |
5485849 | Panescu et al. | Jan 1996 | A |
5496267 | Drasler et al. | Mar 1996 | A |
5499981 | Kordis | Mar 1996 | A |
5531760 | Alwafaie | Jul 1996 | A |
5545193 | Fleischman et al. | Aug 1996 | A |
5555883 | Avitall | Sep 1996 | A |
5557967 | Renger | Sep 1996 | A |
5575810 | Swanson et al. | Nov 1996 | A |
5593424 | Northrup, III | Jan 1997 | A |
5598848 | Swanson et al. | Feb 1997 | A |
5599345 | Edwards et al. | Feb 1997 | A |
5620481 | Desai et al. | Apr 1997 | A |
5637090 | McGee et al. | Jun 1997 | A |
5662587 | Grundfest et al. | Sep 1997 | A |
5681308 | Edward et al. | Oct 1997 | A |
5681336 | Clement et al. | Oct 1997 | A |
5687723 | Avitall | Nov 1997 | A |
5687737 | Branham et al. | Nov 1997 | A |
5697285 | Nappi et al. | Dec 1997 | A |
5713896 | Nardella | Feb 1998 | A |
5713942 | Stern et al. | Feb 1998 | A |
5716397 | Myers | Feb 1998 | A |
5720726 | Marcadis et al. | Feb 1998 | A |
5728114 | Evans et al. | Mar 1998 | A |
5730127 | Avitall | Mar 1998 | A |
5762066 | Law et al. | Jun 1998 | A |
5769846 | Edwards et al. | Jun 1998 | A |
5782239 | Webster, Jr. | Jul 1998 | A |
5782879 | Rosborough et al. | Jul 1998 | A |
5800495 | Machek et al. | Sep 1998 | A |
5823189 | Kordis | Oct 1998 | A |
5824066 | Gross | Oct 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5836990 | Li | Nov 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5868755 | Kanner et al. | Feb 1999 | A |
5876343 | Teo | Mar 1999 | A |
5881727 | Edwards | Mar 1999 | A |
5885278 | Fleischman | Mar 1999 | A |
5891136 | McGee et al. | Apr 1999 | A |
5904711 | Flom et al. | May 1999 | A |
5916163 | Panescu et al. | Jun 1999 | A |
5919207 | Taheri | Jul 1999 | A |
5921924 | Avitall | Jul 1999 | A |
5935075 | Casscells et al. | Aug 1999 | A |
5935079 | Swanson et al. | Aug 1999 | A |
5941251 | Panescu et al. | Aug 1999 | A |
5944715 | Goble et al. | Aug 1999 | A |
5961440 | Schweich, Jr. et al. | Oct 1999 | A |
5968040 | Swanson et al. | Oct 1999 | A |
5984950 | Cragg et al. | Nov 1999 | A |
6001069 | Tachibana et al. | Dec 1999 | A |
6001093 | Swanson et al. | Dec 1999 | A |
6014581 | Whayne et al. | Jan 2000 | A |
6023638 | Swanson | Feb 2000 | A |
6030382 | Fleischman et al. | Feb 2000 | A |
6036689 | Tu et al. | Mar 2000 | A |
6063082 | DeVore et al. | May 2000 | A |
6071282 | Fleischman | Jun 2000 | A |
6104944 | Martinelli | Aug 2000 | A |
6106522 | Fleischman et al. | Aug 2000 | A |
6123702 | Swanson et al. | Sep 2000 | A |
6138043 | Avitall | Oct 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6156046 | Passafaro et al. | Dec 2000 | A |
6210432 | Solem et al. | Apr 2001 | B1 |
6216043 | Swanson et al. | Apr 2001 | B1 |
6217573 | Webster | Apr 2001 | B1 |
6241747 | Ruff | Jun 2001 | B1 |
6248124 | Pedros et al. | Jun 2001 | B1 |
6258258 | Sartori | Jul 2001 | B1 |
6266550 | Selmon et al. | Jul 2001 | B1 |
6304769 | Arenson et al. | Oct 2001 | B1 |
6306135 | Ellman et al. | Oct 2001 | B1 |
6308091 | Avitall | Oct 2001 | B1 |
6319249 | Töllner | Nov 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6330478 | Lee et al. | Dec 2001 | B1 |
6346105 | Tu et al. | Feb 2002 | B1 |
6350263 | Wetzig et al. | Feb 2002 | B1 |
6358258 | Arcia et al. | Mar 2002 | B1 |
6383151 | Diederich et al. | May 2002 | B1 |
6389311 | Whayne et al. | May 2002 | B1 |
6391024 | Sun et al. | May 2002 | B1 |
6391048 | Ginn et al. | May 2002 | B1 |
6391054 | Carpentier et al. | May 2002 | B2 |
6402781 | Langberg et al. | Jun 2002 | B1 |
6436052 | Nikolic et al. | Aug 2002 | B1 |
6475223 | Werp et al. | Nov 2002 | B1 |
6485409 | Voloshin et al. | Nov 2002 | B1 |
6485482 | Belef | Nov 2002 | B1 |
6485489 | Teirstein et al. | Nov 2002 | B2 |
6506210 | Kanner | Jan 2003 | B1 |
6514249 | Maguire et al. | Feb 2003 | B1 |
6529756 | Phan et al. | Mar 2003 | B1 |
6537198 | Vidlund et al. | Mar 2003 | B1 |
6537314 | Langberg et al. | Mar 2003 | B2 |
6540670 | Hirata et al. | Apr 2003 | B1 |
6551310 | Ganz et al. | Apr 2003 | B1 |
6551312 | Zhang et al. | Apr 2003 | B2 |
6569160 | Goldin et al. | May 2003 | B1 |
6569198 | Wilson et al. | May 2003 | B1 |
6575971 | Hauck et al. | Jun 2003 | B2 |
6589208 | Ewers et al. | Jul 2003 | B2 |
6616684 | Vidlund et al. | Sep 2003 | B1 |
6626930 | Allen et al. | Sep 2003 | B1 |
6632238 | Ginn et al. | Oct 2003 | B2 |
6635056 | Kadhiresan et al. | Oct 2003 | B2 |
6640119 | Budd et al. | Oct 2003 | B1 |
6662034 | Segner et al. | Dec 2003 | B2 |
D484979 | Fontaine | Jan 2004 | S |
6704590 | Haldeman | Mar 2004 | B2 |
6723038 | Schroeder et al. | Apr 2004 | B1 |
6726716 | Marquez | Apr 2004 | B2 |
6760616 | Hoey et al. | Jul 2004 | B2 |
6780197 | Roe et al. | Aug 2004 | B2 |
6788969 | Dupree et al. | Sep 2004 | B2 |
6797001 | Mathis et al. | Sep 2004 | B2 |
6800090 | Alferness et al. | Oct 2004 | B2 |
6824562 | Mathis et al. | Nov 2004 | B2 |
6837886 | Collins et al. | Jan 2005 | B2 |
6852076 | Nikolic et al. | Feb 2005 | B2 |
6855143 | Davison et al. | Feb 2005 | B2 |
6890353 | Cohn et al. | May 2005 | B2 |
6892091 | Ben-Haim et al. | May 2005 | B1 |
6899674 | Viebach et al. | May 2005 | B2 |
6907297 | Wellman et al. | Jun 2005 | B2 |
6908478 | Alferness et al. | Jun 2005 | B2 |
6913576 | Bowman | Jul 2005 | B2 |
6918903 | Bass | Jul 2005 | B2 |
6926669 | Stewart et al. | Aug 2005 | B1 |
6942657 | Sinofsky et al. | Sep 2005 | B2 |
6949122 | Adams et al. | Sep 2005 | B2 |
6960206 | Keane | Nov 2005 | B2 |
6960229 | Mathis et al. | Nov 2005 | B2 |
6986775 | Morales et al. | Jan 2006 | B2 |
6989010 | Francischelli et al. | Jan 2006 | B2 |
6989028 | Lashinski et al. | Jan 2006 | B2 |
6994093 | Murphy et al. | Feb 2006 | B2 |
6997951 | Solem et al. | Feb 2006 | B2 |
7001383 | Keidar | Feb 2006 | B2 |
7025776 | Houser et al. | Apr 2006 | B1 |
7048734 | Fleischman et al. | May 2006 | B1 |
7050848 | Hoey et al. | May 2006 | B2 |
7052487 | Cohn et al. | May 2006 | B2 |
7068867 | Adoram et al. | Jun 2006 | B2 |
7141019 | Pearlman | Nov 2006 | B2 |
7144363 | Pai et al. | Dec 2006 | B2 |
7166127 | Spence et al. | Jan 2007 | B2 |
7174201 | Govari et al. | Feb 2007 | B2 |
7177677 | Kaula et al. | Feb 2007 | B2 |
7186210 | Feld et al. | Mar 2007 | B2 |
7187964 | Khoury | Mar 2007 | B2 |
7189202 | Lau et al. | Mar 2007 | B2 |
7255695 | Falwell et al. | Aug 2007 | B2 |
7276044 | Ferry et al. | Oct 2007 | B2 |
7279007 | Nikolic et al. | Oct 2007 | B2 |
7300435 | Wham et al. | Nov 2007 | B2 |
7303526 | Sharkey et al. | Dec 2007 | B2 |
7335196 | Swanson et al. | Feb 2008 | B2 |
7481808 | Koyfman et al. | Jan 2009 | B2 |
7507252 | Lashinski et al. | Mar 2009 | B2 |
7530980 | Hooven | May 2009 | B2 |
7736388 | Goldfarb et al. | Jun 2010 | B2 |
7738967 | Salo | Jun 2010 | B2 |
8103338 | Harlev et al. | Jan 2012 | B2 |
D654588 | Taube et al. | Feb 2012 | S |
8118853 | Grewe | Feb 2012 | B2 |
8150499 | Gelbart et al. | Apr 2012 | B2 |
D660967 | Braido et al. | May 2012 | S |
8224432 | MacAdam et al. | Jul 2012 | B2 |
D717954 | Hjelle et al. | Nov 2014 | S |
9198713 | Wallace et al. | Dec 2015 | B2 |
20010003158 | Kensey et al. | Jun 2001 | A1 |
20010005787 | Oz et al. | Jun 2001 | A1 |
20010018611 | Solem et al. | Aug 2001 | A1 |
20010020126 | Swanson et al. | Sep 2001 | A1 |
20010021867 | Kordis et al. | Sep 2001 | A1 |
20020002329 | Avitall | Jan 2002 | A1 |
20020016628 | Langberg et al. | Feb 2002 | A1 |
20020087156 | Maguire et al. | Jul 2002 | A1 |
20020087173 | Alferness et al. | Jul 2002 | A1 |
20020099415 | Panescu et al. | Jul 2002 | A1 |
20020107478 | Wendlandt | Aug 2002 | A1 |
20020107511 | Collins et al. | Aug 2002 | A1 |
20020107530 | Saucer et al. | Aug 2002 | A1 |
20020115941 | Whayne et al. | Aug 2002 | A1 |
20020115944 | Mendes et al. | Aug 2002 | A1 |
20020169504 | Alferness et al. | Nov 2002 | A1 |
20020177782 | Penner | Nov 2002 | A1 |
20020183836 | Liddicoat et al. | Dec 2002 | A1 |
20020183841 | Cohn et al. | Dec 2002 | A1 |
20020188170 | Santamore et al. | Dec 2002 | A1 |
20030028118 | Dupree et al. | Feb 2003 | A1 |
20030028183 | Sanchez et al. | Feb 2003 | A1 |
20030050685 | Nikolic et al. | Mar 2003 | A1 |
20030055420 | Kadhiresan et al. | Mar 2003 | A1 |
20030069570 | Witzel et al. | Apr 2003 | A1 |
20030069636 | Solem et al. | Apr 2003 | A1 |
20030078465 | Pai et al. | Apr 2003 | A1 |
20030078671 | Lesniak et al. | Apr 2003 | A1 |
20030105384 | Sharkey et al. | Jun 2003 | A1 |
20030105520 | Alferness et al. | Jun 2003 | A1 |
20030109770 | Sharkey et al. | Jun 2003 | A1 |
20030176810 | Maahs et al. | Sep 2003 | A1 |
20030181819 | Desai | Sep 2003 | A1 |
20030229395 | Cox | Dec 2003 | A1 |
20040002626 | Feld et al. | Jan 2004 | A1 |
20040054279 | Hanley | Mar 2004 | A1 |
20040133220 | Lashinski et al. | Jul 2004 | A1 |
20040133273 | Cox | Jul 2004 | A1 |
20040138744 | Lashinski et al. | Jul 2004 | A1 |
20040153146 | Lashinski et al. | Aug 2004 | A1 |
20040158321 | Reuter et al. | Aug 2004 | A1 |
20040176797 | Opolski | Sep 2004 | A1 |
20040181139 | Falwell et al. | Sep 2004 | A1 |
20040186566 | Hindrichs et al. | Sep 2004 | A1 |
20040215232 | Belhe et al. | Oct 2004 | A1 |
20040243170 | Suresh et al. | Dec 2004 | A1 |
20040249408 | Murphy et al. | Dec 2004 | A1 |
20040249453 | Cartledge et al. | Dec 2004 | A1 |
20040267358 | Reitan | Dec 2004 | A1 |
20050004668 | Aklog et al. | Jan 2005 | A1 |
20050015109 | Lichtenstein | Jan 2005 | A1 |
20050054938 | Wehman et al. | Mar 2005 | A1 |
20050055089 | Macoviak et al. | Mar 2005 | A1 |
20050060030 | Lashinski et al. | Mar 2005 | A1 |
20050064665 | Han | Mar 2005 | A1 |
20050065420 | Collins et al. | Mar 2005 | A1 |
20050065504 | Melsky et al. | Mar 2005 | A1 |
20050080402 | Santamore et al. | Apr 2005 | A1 |
20050096047 | Haberman et al. | May 2005 | A1 |
20050096647 | Steinke et al. | May 2005 | A1 |
20050107723 | Wehman et al. | May 2005 | A1 |
20050107871 | Realyvasques et al. | May 2005 | A1 |
20050125030 | Forsberg et al. | Jun 2005 | A1 |
20050148892 | Desai | Jul 2005 | A1 |
20050149014 | Hauck et al. | Jul 2005 | A1 |
20050149159 | Andreas et al. | Jul 2005 | A1 |
20050154252 | Sharkey et al. | Jul 2005 | A1 |
20050182365 | Hennemann | Aug 2005 | A1 |
20050187620 | Pai et al. | Aug 2005 | A1 |
20050197593 | Burbank et al. | Sep 2005 | A1 |
20050197692 | Pai et al. | Sep 2005 | A1 |
20050197693 | Pai et al. | Sep 2005 | A1 |
20050197694 | Pai et al. | Sep 2005 | A1 |
20050203558 | Maschke | Sep 2005 | A1 |
20050209636 | Widomski et al. | Sep 2005 | A1 |
20050216054 | Widomski et al. | Sep 2005 | A1 |
20050240249 | Tu et al. | Oct 2005 | A1 |
20050251116 | Steinke et al. | Nov 2005 | A1 |
20050251132 | Oral et al. | Nov 2005 | A1 |
20050256521 | Kozel | Nov 2005 | A1 |
20050261580 | Willis et al. | Nov 2005 | A1 |
20050267458 | Paul et al. | Dec 2005 | A1 |
20050267574 | Cohn et al. | Dec 2005 | A1 |
20060009755 | Sra | Jan 2006 | A1 |
20060009756 | Francischelli et al. | Jan 2006 | A1 |
20060014998 | Sharkey et al. | Jan 2006 | A1 |
20060015002 | Moaddeb et al. | Jan 2006 | A1 |
20060015003 | Moaddes et al. | Jan 2006 | A1 |
20060015038 | Weymarn-Scharli | Jan 2006 | A1 |
20060015096 | Hauck et al. | Jan 2006 | A1 |
20060025800 | Suresh | Feb 2006 | A1 |
20060030881 | Sharkey et al. | Feb 2006 | A1 |
20060085049 | Cory et al. | Apr 2006 | A1 |
20060089637 | Werneth et al. | Apr 2006 | A1 |
20060100618 | Chan et al. | May 2006 | A1 |
20060106298 | Ahmed et al. | May 2006 | A1 |
20060135968 | Schaller | Jun 2006 | A1 |
20060135970 | Schaller | Jun 2006 | A1 |
20060184242 | Lichtenstein | Aug 2006 | A1 |
20060199995 | Vijay | Sep 2006 | A1 |
20060229491 | Sharkey et al. | Oct 2006 | A1 |
20060235286 | Stone et al. | Oct 2006 | A1 |
20060235314 | Migliuolo et al. | Oct 2006 | A1 |
20060264980 | Khairkhahan et al. | Nov 2006 | A1 |
20060281965 | Khairkhahan et al. | Dec 2006 | A1 |
20060293698 | Douk | Dec 2006 | A1 |
20060293725 | Rubinsky et al. | Dec 2006 | A1 |
20070016068 | Grunwald et al. | Jan 2007 | A1 |
20070027533 | Douk | Feb 2007 | A1 |
20070038208 | Kefer | Feb 2007 | A1 |
20070083193 | Werneth et al. | Apr 2007 | A1 |
20070083195 | Werneth et al. | Apr 2007 | A1 |
20070088362 | Bonutti et al. | Apr 2007 | A1 |
20070115390 | Makara et al. | May 2007 | A1 |
20070118215 | Moaddeb | May 2007 | A1 |
20070129717 | Brown, III et al. | Jun 2007 | A1 |
20070161846 | Nikolic et al. | Jul 2007 | A1 |
20070198058 | Gelbart et al. | Aug 2007 | A1 |
20070213578 | Khairkhahan et al. | Sep 2007 | A1 |
20070213815 | Khairkhahan et al. | Sep 2007 | A1 |
20070232858 | MacNamara et al. | Oct 2007 | A1 |
20070249999 | Sklar et al. | Oct 2007 | A1 |
20070270688 | Gelbart et al. | Nov 2007 | A1 |
20070299343 | Waters | Dec 2007 | A1 |
20080004534 | Gelbart et al. | Jan 2008 | A1 |
20080004643 | To et al. | Jan 2008 | A1 |
20080004697 | Lichtenstein et al. | Jan 2008 | A1 |
20080045778 | Lichtenstein et al. | Feb 2008 | A1 |
20080071298 | Khairkhahan et al. | Mar 2008 | A1 |
20080262337 | Falwell et al. | Oct 2008 | A1 |
20080281322 | Sherman et al. | Nov 2008 | A1 |
20080312713 | Wilfley et al. | Dec 2008 | A1 |
20090018617 | Skelton et al. | Jan 2009 | A1 |
20090024138 | Saleh | Jan 2009 | A1 |
20090069704 | MacAdam et al. | Mar 2009 | A1 |
20090131930 | Gelbart et al. | May 2009 | A1 |
20090157058 | Ferren et al. | Jun 2009 | A1 |
20090171274 | Harlev et al. | Jul 2009 | A1 |
20090192441 | Gelbart et al. | Jul 2009 | A1 |
20090270737 | Thornton | Oct 2009 | A1 |
20090287271 | Blum et al. | Nov 2009 | A1 |
20090287304 | Dahlgren et al. | Nov 2009 | A1 |
20100121147 | Oskin et al. | May 2010 | A1 |
20100211052 | Brown et al. | Aug 2010 | A1 |
20100249771 | Pearson et al. | Sep 2010 | A1 |
20100268059 | Ryu et al. | Oct 2010 | A1 |
20110125172 | Gelbart et al. | May 2011 | A1 |
20110172658 | Gelbart et al. | Jul 2011 | A1 |
20110282491 | Prisco et al. | Nov 2011 | A1 |
20120158016 | Gelbart et al. | Jun 2012 | A1 |
20120165829 | Chen et al. | Jun 2012 | A1 |
20120271135 | Burke et al. | Oct 2012 | A1 |
20130165916 | Mathur et al. | Jun 2013 | A1 |
20130172883 | Lopes et al. | Jul 2013 | A1 |
20130178850 | Lopes et al. | Jul 2013 | A1 |
20130178851 | Lopes et al. | Jul 2013 | A1 |
20130184705 | Gelbart et al. | Jul 2013 | A1 |
20130184706 | Gelbart et al. | Jul 2013 | A1 |
20130197513 | Lopes et al. | Aug 2013 | A1 |
20130241929 | Massarwa et al. | Sep 2013 | A1 |
20130304065 | Lopes et al. | Nov 2013 | A1 |
20130310828 | Reinders et al. | Nov 2013 | A1 |
20140114307 | Moisa et al. | Apr 2014 | A1 |
20140350552 | Highsmith | Nov 2014 | A1 |
20150126993 | Gelbart et al. | May 2015 | A1 |
Number | Date | Country |
---|---|---|
101797181 | Aug 2010 | CN |
0723467 | Apr 2002 | EP |
9510320 | Apr 1995 | WO |
9520349 | Aug 1995 | WO |
9717892 | May 1997 | WO |
0108575 | Feb 2001 | WO |
WO 02087437 | Nov 2002 | WO |
03015611 | Feb 2003 | WO |
03077800 | Sep 2003 | WO |
2004012629 | Feb 2004 | WO |
2004047679 | Jun 2004 | WO |
2004084746 | Oct 2004 | WO |
2004100803 | Nov 2004 | WO |
2005070330 | Aug 2005 | WO |
2005102181 | Nov 2005 | WO |
2006017809 | Feb 2006 | WO |
2006105121 | Oct 2006 | WO |
2006135747 | Dec 2006 | WO |
2006135749 | Dec 2006 | WO |
2007021647 | Feb 2007 | WO |
2007115390 | Oct 2007 | WO |
2008002606 | Jan 2008 | WO |
2009011721 | Jan 2009 | WO |
2009065042 | May 2009 | WO |
2012100184 | Jul 2012 | WO |
2012100185 | Jul 2012 | WO |
2013173917 | Nov 2013 | WO |
Entry |
---|
Gelbart et al, “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Notice of Allowance dated Oct. 23, 2014 for U.S. Appl. No. 11/475,950, 10 pgs. |
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Supplemental Notice of Allowance dated Oct. 6, 2014 for U.S. Appl. No. 11/941,819, 4 pgs. |
Gelbart et al., Medical Device for Use in Bodily Lumens, for Example an Atrium, Amendment filed Sep. 22, 2014, for co-pending U.S. Appl. No. 13/070,215, 18 pgs. |
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Notice of Allowance mailed Nov. 13, 2014 for U.S. Appl. No. 13/070,215, 54 pages. |
Official Action issued in CN201280004400.9, mailed Dec. 3, 2014. |
International Search Report and Written Opinion mailed Aug. 2, 2013 issued in PCT/CA2013/050350. |
International Search Report and Written Opinion mailed Sep. 17, 2013 issued in PCT/US2013/039982. |
International Search Report and Written Opinion mailed Sep. 27, 2013 issued in PCT/US2013/039977. |
Non-final Office Action issued in co-pending U.S. Appl. No. 13/782,867, dated Apr. 15, 2015. |
Non-final Office Action issued in co-pending U.S. Appl. No. 13/782,903, dated Apr. 28, 2015. |
Extended European Search Report for corresponding EP 12736677.1, mail date Mar. 28, 2014. |
Extended European Search Report for corresponding EP 12736962.7, mail date Mar. 28, 2014. |
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Office Action mailed May 22, 2015 for U.S. Appl. No. 13/782,889, 86 pages. |
Becker, et al., “Ablation of Atrial Fibrillation: Energy Sources and Navigation Tools: A Review”, Journal of Electrocardiology, vol. 37, Supplement 2004, pp. 55-62. |
Buchbinder, Maurice, “Dynamic Mitral Valve Annuloplasty: A Reshapable Ring for Residual and Recurring MR”, Foundation for Cardiovascular Medicine, May 24, 2007. |
Calkins, Hugh, “Electrophysiology: Radiofrequency Catheter Ablation of Supraventricular Arrhythmias”, Heart, 2001; 85; pp. 594-600. |
De Ponti, et al., “Non-Fluoroscopic Mapping Systems for Electrophysiology: the Tool or Toy Dilemma After 10 Years”, European Heart Journal, 2006; 27, pp. 1134-1136. |
Gabriel, et al., “The Dielectric Properties of Biological Tissues: I. Literature Survey”, Phys. Med. Biol.; 41, 1996, pp. 2231-2249. |
Konings, et al., “Development of an Intravascular Impedance Catheter for Detection of Fatty Lesions in Arteries”, IEEE Transactions on Medical Imaging, vol. 16, No. 4, Aug. 1997, pp. 439-446. |
Mack, Michael J., “New Techniques for Percutaneous Repair of the Mitral Valve”, Heart Fail Rev, 2006; 11, pp. 259-268. |
Otasevic, et al., “First-in-Man Implantation of Left Ventricular Partitioning Device in a Patient With Chronic Heart Failure: Twelve-Month Follow-Up”, Journal of Cardiac Failure, vol. 13, No. 7, 2007, pp. 517-520. |
Sharkey, et al., “Left Ventricular Apex Occluder. Description of a Ventricular Partitioning Device”, EuroIntervention, 2006, pp. 125-127. |
Stiles, et al., “Simulated Characterization of Atherosclerotic Lesions in the Coronary Arteries by Measurement of Bioimpedance”, IEEE Transactions on Biomedical Engineering, vol. 50, No. 7, Jul. 2003, pp. 916-921. |
Tanaka, et al., “Artificial SMA Valve for Treatment of Urinary Incontinence: Upgrading of Valve and Introduction of Transcutaneous Transformer”, Bio-Medical Materials and Engineering; vol. 9, 1999, pp. 97-112. |
Timek, et al., “Septal-Lateral Annular Cinching Abolishes Acute Ischemic Mitral Regurgitation”, Journal of Thoracic and Cardiovascular Surgery, vol. 123, No. 5, May 2002, pp. 881-888. |
Timek, et al., “Septal-Lateral Annular Cinching (SLAC) Reduces Mitral Annular Size Without Perturbing Normal Annular Dynamics”, Journal of Heart Valve Disease, vol. 11, No. 1, Jan. 2002. |
Valvano, et al., “Thermal Conductivity and Diffusivity of Biomaterials Measured with Self-Heated Thermistors”, International Journal of Thermophysics, vol. 6, No. 3, 1985, pp. 301-311. |
International Search Report, mailed Dec. 5, 2007 for PCT/US2007/014902, 5 pages. |
International Search Report, mailed Dec. 2, 2009 for PCT/US2008/083644, 5 pages. |
International Preliminary Report on Patentability, issued Jan. 6, 2009 for PCT/US2007/014902, 8 pages. |
Written Opinion, mailed Dec. 5, 2007, for PCT/US2007/014902, 7 pages. |
Written Opinion, mailed Dec. 2, 2009, for PCT/US2008/083644, 9 pages. |
“Phased RF Catheter Ablation System”, 2014 Medtronic Inc., 2 pgs, http://www.medtronic.eu/your-health/atrial-fibrillation/about-the-therapy/our-phased-rf-ablation-system/[Jun. 24, 2014 2:38:05 PM]. |
“ThermoCool® Irrigated Tip Catheter”, Brochure, Biosense Webster, 4 pgs, Biosense Webster, Inc. 3333 Diamond Canyon Road Diamond Bar, CA 91765, USA, © Biosense Webster, Inc. 2009 All rights reserved. 1109003.0. |
BIOTRONIK'S “AlCath Flutter Gold Cath for Atrial Flutter Available in EU”, medGadget, 3 pgs, http://www.medgadget.com/2013/09/biotroniks-alcath-flutter-gold-cath-for-atrial-flutter-unveiled-in-europe.html[Jun. 24, 2014 2:37:09 PM]. |
Extended European Search Report mailed Aug. 20, 2013 issued in EP Patent Application No. 13172848.7. |
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Pre Amend filed Aug. 29, 2007 for U.S. Appl. No. 11/475,950, 42 pgs. |
Gelbart et al., “Automatic Atherectomy System”, Amendment filed Oct. 25, 2010 for U.S. Appl. No. 11/436,584, 9 pgs. |
Gelbart et al., “Automatic Atherectomy System”, Amendment filed Mar. 30, 2010 for U.S. Appl. No. 11/436,584, 20 pgs. |
Gelbart et al., “Automatic Atherectomy System”, Amendment filed Aug. 4, 2009 for U.S. Appl. No. 11/436,584, 35 pgs. |
Gelbart et al., “Automatic Atherectomy System”, Amendment filed Sep. 15, 2011 for U.S. Appl. No. 12/950,871, 21 pgs. |
Gelbart et al., “Automatic Atherectomy System”, Office Action mailed Jun. 15, 2011 for U.S. Appl. No. 12/950,871, 16 pgs. |
Gelbart et al., “Automatic Atherectomy System”, Office Action mailed Dec. 1, 2009 for U.S. Appl. No. 11/436,584, 8 pgs. |
Gelbart et al., “Automatic Atherectomy System”, Office Action mailed Dec. 14, 2010 for U.S. Appl. No. 11/436,584, 12 pgs. |
Gelbart et al., “Automatic Atherectomy System”, Office Action mailed Mar. 4, 2009 for U.S. Appl. No. 11/436,584, 6 pgs. |
Bard, “HD Mesh Ablator Catheter”, Brochure, 2008, 4 pgs, Bard Electrophysiology Division, C.R. Bard Inc., 55 Technology Drive Lowell, MA 01851 USA. |
“Constellation Mapping Catheters”, Brochure, Boston Scientific Corp., 2 pgs, © 2007 Boston Scientific Corporation. |
Written opinion dated Jul. 30, 2012 for PCT/US2012/022062, 5 pgs. |
Written opinion dated Aug. 22, 2012 for PCT/US2012/022061, 6 pgs. |
International Search Report dated Aug. 22, 2012 for PCT/US2012/022061, 5 pgs. |
International Search Report dated Jul. 30, 2012 for PCT/US2012/022062, 5 pgs. |
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Office Action mailed Jul. 25, 2011 for U.S. Appl. No. 11/941,819, now published as US 2009-0131930 A1. |
Gelbart et al., “Liposuction System”, Amendment filed Jun. 10, 2011 for U.S. Appl. No. 12/010,458, 10 pgs. |
Gelbart et al., “Liposuction System”, Amendment filed Dec. 7, 2011 for U.S. Appl. No. 12/010,458, 15 pgs. |
Gelbart et al., “Liposuction System”, Office Action mailed Mar. 16, 2011 for U.S. Appl. No. 12/010,458, 12 pgs. |
Gelbart et al., “Liposuction System”, Office Action mailed Sep. 14, 2011 for U.S. Appl. No. 12/010,458, 9 pgs. |
“Waveforms and Segments”, Ensite System Instructions for use, 54-06154-001 Rev02, Chapter 7 , pp. 85-90 © 2007 St. Jude Medical. |
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Amendment filed Feb. 23, 2011 for U.S. Appl. No. 11/475,950, 28 pgs. |
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Amendment filed Mar. 5, 2008 for U.S. Appl. No. 11/475,950, 11 pgs. |
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Amendment filed Aug. 16, 2010 for U.S. Appl. No. 11/475,950, 22 pgs. |
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Office Action mailed Nov. 23, 2010 for U.S. Appl. No. 11/475,950, 25 pgs. |
Gelbart et al., “Intra-Cardiac Mapping and Ablation Method”, Office Action mailed Jun. 23, 2010 for U.S. Appl. No. 11/475,950, 18 pgs. |
Gelbart et al, “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Office Action dated Dec. 13, 2013; Notice of Allowance dated Jul. 25, 2014 for co-pending U.S. Appl. No. 11/475,950, 19 pgs. |
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Office Action dated Jan. 3, 2012; Office Action dated Apr. 3, 2014; Notice of Allowance dated Aug. 26, 2014 for co-pending U.S. Appl. No. 11/941,819, 35 pgs. |
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Office Action dated Jun. 20, 2014, for co-pending U.S. Appl. No. 13/070,215, 8 pgs. |
Gelbart et al, “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Amendment filed Apr. 10, 2014; Supplemental Amendment filed Feb. 12, 2013 for co-pending U.S. Appl. No. 11/475,950, 21 pgs. |
Gelbart et al, “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Preliminary Amendment filed Aug. 22, 2014; Preliminary Amendment filed Mar. 5, 2013 for co-pending U.S. Appl. No. 13/785,910, 10 pgs. |
Gelbart et al, “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Preliminary Amendment filed Aug. 22, 2014; Preliminary Amendment filed Mar. 5, 2013 for co-pending U.S. Appl. No. 13/785,931, 10 pgs. |
Lopes et al, “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Preliminary Amendment filed Oct. 22, 2013 for co-pending U.S. Appl. No. 13/942,354, 13 pgs. |
Lopes et al, “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Preliminary Amendment filed Aug. 20, 2014 for co-pending U.S. Appl. No. 13/782,889, 11 pgs. |
Lopes et al, “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Preliminary Amendment filed Mar. 14, 2013 for co-pending U.S. Appl. No. 13/782,867, 8 pgs. |
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Amendment filed Jul. 3, 2014; Amendment filed Apr. 2, 2012; Amendment filed Mar. 1, 2012; Amendment filed Nov. 23, 2011; Replacement drawings filed Feb. 13, 2008 for U.S. Appl. No. 11/941,819, 155 pgs. |
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Preliminary Amendment filed May 12, 2014; Preliminary Amendment filed May 2, 2014 for U.S. Appl. No. 14/229,305, 12 pgs. |
Gelbart et al., “Medical Device for Use in Bodily Lumens, for Example an Atrium”, Preliminary Amendment filed May 12, 2014; Preliminary Amendment filed May 2, 2014 for U.S. Appl. No. 14/229,250, 10 pgs. |
International Search Report mailed Mar. 10, 2015, for International Application PCT/CA2014/051144; 10 pages. |
Written Opinion mailed Mar. 10, 2015, for International Application PCT/CA2014/051144; 4 pages. |
BIOTRONIK'S “AlCath Flutter Gold Cath for Atrial Flutter Available in EU”, Sep. 19, 2013, medGadget, 3 pgs, http://www.medgadget.com/2013/09/biotroniks-alcath-flutter-gold-cath-for-atrial-flutter-unveiled-in-europe.html [Jun. 24, 2014 2:37:09 PM]. |
Examination Report issued in EP13172848.7, mailed Sep. 21, 2015. |
Extended European Search Report issued in EP13793216.6, mailed Oct. 30, 2015. |
Moisa et al., “Catheter System ”, Office Action mailed Nov. 16, 2015 for U.S. Appl. No. 14/136,946, 92 pages. |
Office Action issued in U.S. Appl. No. 13/782,889, mailed Dec. 18, 2015. |
Office Action issued in U.S. Appl. No. 13/782,903, mailed Dec. 18, 2015. |
Extended European Search Report issued in EP15188407.9, mailed Jan. 21, 2016. |
Lopes et al. “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Office Action mailed Jan. 25, 2016 for U.S. Appl. No. 13/782,867, 49 pages. |
Notice of Allowance issued in U.S. Appl. No. 13/793,076, dated Feb. 10, 2016. |
Gelbart et al., “Apparatus and Method for Intra-Cardiac Mapping and Ablation”, Office Action mailed Aug. 5, 2015 for U.S. Appl. No. 13/785,910, 79 pages. |
Lopes et al., “High-Density Electrode-Based Medical Device System”, Office Action mailed Jul. 10, 2015 for U.S. Appl. No. 13/793,076, 98 pages. |
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Amendment filed Aug. 24, 2015 for U.S. Appl. No. 13/782,889, 21 pages. |
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Amendment filed Aug. 28, 2015 for U.S. Appl. No. 13/782,903, 19 pages. |
Lopes et al., “Enhanced Medical Device for Use in Bodily Cavities, for Example an Atrium”, Amendment filed Sep. 14, 2015 for U.S. Appl. No. 13/782,867, 25 pages. |
Lopes et al., “High-Density Electrode-Based Medical Device System ”, Amendment filed Oct. 9, 2015 for U.S. Appl. No. 13/793,076, 14 pages. |
Final Office Action issued in U.S. Appl. No. 13/793,213, dated Feb. 26, 2016. |
Non-Final Office Action issued in U.S. Appl. No. 29/509,719, dated Feb. 25, 2016. |
Quayle issued in U.S. Appl. No. 29/509,621, dated Feb. 26, 2016. |
Quayle issued in U.S. Appl. No. 29/509,636, dated Feb. 26, 2016. |
Non-Final Office Action issued in U.S. Appl. No. 13/785,910 mailed Apr. 8, 2016. |
Non-Final Office Action issued in U.S. Appl. No. 14/229,250 mailed Apr. 28, 2016. |
Non-Final Office Action issued in U.S. Appl. No. 14/229,305 mailed Apr. 29, 2016. |
Notice of Allowance issued in U.S. Appl. No. 14/136,946 mailed May 12, 2016. |
Number | Date | Country | |
---|---|---|---|
20130190587 A1 | Jul 2013 | US |
Number | Date | Country | |
---|---|---|---|
61723311 | Nov 2012 | US | |
61670881 | Jul 2012 | US | |
61649734 | May 2012 | US | |
61734750 | Dec 2012 | US | |
61435213 | Jan 2011 | US | |
61485987 | May 2011 | US | |
61488639 | May 2011 | US | |
61515141 | Aug 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2012/022061 | Jan 2012 | US |
Child | 13793213 | US | |
Parent | PCT/US2012/022062 | Jan 2012 | US |
Child | PCT/US2012/022061 | US |